Home LiteratureArticle Details
PMID: 11413323 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Immunoglobulin G3 from polyclonal human immunodeficiency virus (HIV) immune globulin is more potent than other subclasses in neutralizing HIV type 1.

Journal of virology ·Vol. 75 ·No. 14 ·2001-07-00 ·Pages 6558-65

Scharf O, Golding H, King LR, Eller N, Frazier D, Golding B, Scott DE

Abstract

Passive antibody prophylaxis against human immunodeficiency virus type 1 (HIV-1) has been accomplished in primates, suggesting that this strategy may prove useful in humans. While antibody specificity is crucial for neutralization, other antibody characteristics, such as subclass, have not been explored. Our objective was to compare the efficiencies of immunoglobulin G (IgG) subclasses from polyclonal human HIV immune globulin (HIVIG) in the neutralization of HIV-1 strains differing in coreceptor tropism. IgG1, IgG2, and IgG3 were enriched from HIVIG by using protein A-Sepharose. All three subclasses bound major HIV-1 proteins, as shown by Western blot assay and enzyme-linked immunosorbent assay. In HIV-1 fusion assays using X4, R5, or X4R5 envelope-expressing effector cells, IgG3 more efficiently blocked fusion. In neutralization assays with cell-free viruses using X4 (LAI, IIIB), R5 (BaL), and X4R5 (DH123), a similar hierarchy of neutralization was found: IgG3 > IgG1 > IgG2. IgG3 has a longer, more flexible hinge region than the other subclasses. To test whether this is important, IgG1 and IgG3 were digested with pepsin to generate F(ab')(2) fragments or with papain to generate Fab fragments. IgG3 F(ab')(2) fragments were still more efficient in neutralization than F(ab')(2) of IgG1. However, Fab fragments of IgG3 and IgG1 demonstrated equivalent neutralization capacities and the IgG3 advantage was lost. These results suggest that the IgG3 hinge region confers enhanced HIV-neutralizing ability. Enrichment and stabilization of IgG3 may therefore lead to improved HIVIG preparations. The results of this study have implications for the improvement of passive immunization with polyclonal or monoclonal antibodies and suggest that HIV-1 vaccines which induce high-titer IgG3 responses could be advantageous.

MeSH Terms
Antibodies, Viral/immunology HIV Infections/prevention & control HIV-1/immunology Humans Immunoglobulin Fab Fragments/immunology Immunoglobulin G/immunology Neutralization Tests
Chemicals
Antibodies, Viral Immunoglobulin Fab Fragments Immunoglobulin G
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Scharf O
Division of Hematology, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA.
Golding H
King L R
Eller N
Frazier D
Golding B
Scott D E
References (43)
43 references, click to expand
  1. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Nat Med. 2000 Feb;6(2):200-6 PMID: 10655110
  2. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.
    J Virol. 1997 Oct;71(10):7198-206 PMID: 9311792
  3. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273).
    J Infect Dis. 2000 Feb;181(2):548-54 PMID: 10669338
  4. Metabolic properties of IgG subclasses in man.
    J Clin Invest. 1970 Apr;49(4):673-80 PMID: 5443170
  5. The G4 subclass in IgG fractions prepared by ion-exchange chromatography.
    J Immunol. 1970 May;104(5):1310-2 PMID: 4986370
  6. Papain sensitivity of heavy chain sub-classes in normal human IgG and localizaton of antigenic determinants for the sub-classes.
    Immunochemistry. 1971 Mar;8(3):243-50 PMID: 4113947
  7. Primary structure of the "hinge" region of human IgG3. Probable quadruplication of a 15-amino acid residue basic unit.
    J Biol Chem. 1977 Feb 10;252(3):883-9 PMID: 402363
  8. Immune globulins.
    Semin Thromb Hemost. 1979;6(1):44-74 PMID: 117551
  9. pH gradient elution of human IgG1, IgG2 and IgG4 from protein A-sepharose.
    J Immunol Methods. 1979;31(3-4):211-7 PMID: 42659
  10. IgG subclasses in human gamma-globulin preparations for intravenous use and their reactivity with staphylococcus protein A.
    Vox Sang. 1980;38(3):147-55 PMID: 6155736
  11. Prophylaxis of varicella in high-risk children: dose-response effect of zoster immune globulin.
    J Pediatr. 1981 Mar;98(3):368-73 PMID: 7205447
  12. Correlation between segmental flexibility and effector function of antibodies.
    Nature. 1984 Jan 12-18;307(5947):136-40 PMID: 6690993
  13. Antibody-antigen flexibility.
    Nature. 1987 Mar 26-Apr 1;326(6111):334-5 PMID: 3561477
  14. Intravenous immunoglobulins as therapeutic agents.
    Ann Intern Med. 1987 Sep;107(3):367-82 PMID: 3304051
  15. Differences among available immunoglobulin preparations for intravenous use.
    Pediatr Infect Dis J. 1988 May;7(5 Suppl):S43-8 PMID: 2456510
  16. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
    EMBO J. 1988 Jul;7(7):1989-94 PMID: 3138110
  17. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.
    Nature. 1990 Jun 14;345(6276):622-5 PMID: 2190095
  18. Biological and immunological properties of human immunodeficiency virus type 1 envelope glycoprotein: analysis of proteins with truncations and deletions expressed by recombinant vaccinia viruses.
    J Virol. 1991 Jan;65(1):31-41 PMID: 1985202
  19. Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors.
    Blood. 1991 Mar 1;77(5):1111-7 PMID: 1995097
  20. Prevention of HIV infection by passive immunization with HIV immunoglobulin.
    AIDS Res Hum Retroviruses. 1991 Dec;7(12):971-3 PMID: 1812946
  21. Intermolecular cooperativity: a clue to why mice have IgG3?
    Immunol Today. 1992 May;13(5):164-8 PMID: 1642754
  22. Functional activity of an HIV-1 neutralizing IgG human monoclonal antibody: ADCC and complement-mediated lysis.
    AIDS Res Hum Retroviruses. 1992 May;8(5):553-8 PMID: 1381201
  23. An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.
    J Virol. 1992 Dec;66(12):7517-21 PMID: 1433527
  24. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody.
    J Virol. 1992 Dec;66(12):7538-42 PMID: 1433529
  25. Live, attenuated simian immunodeficiency virus vaccines elicit potent resistance against a challenge with a human immunodeficiency virus type 1 chimeric virus.
    J Virol. 1997 Nov;71(11):8141-8 PMID: 9343164
  26. beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques.
    Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10803-8 PMID: 9724785
  27. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
    J Virol. 1998 Dec;72(12):9788-94 PMID: 9811714
  28. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Nat Med. 1999 Feb;5(2):204-10 PMID: 9930869
  29. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
    J Infect Dis. 1999 Mar;179(3):567-75 PMID: 9952362
  30. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  31. Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG.
    AIDS Res Hum Retroviruses. 1992 Aug;8(8):1515 PMID: 1466993
  32. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.
    J Immunol. 1993 Jan 15;150(2):635-43 PMID: 7678279
  33. A human lymphoid recombinant cell line with functional human immunodeficiency virus type 1 envelope.
    AIDS Res Hum Retroviruses. 1993 Jan;9(1):23-32 PMID: 8094000
  34. Role of heavy chain constant domains in antibody-antigen interaction. Apparent specificity differences among streptococcal IgG antibodies expressing identical variable domains.
    J Immunol. 1993 Mar 15;150(6):2231-42 PMID: 7680687
  35. Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance.
    Mol Immunol. 1994 Jun;31(8):577-84 PMID: 7515151
  36. HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.
    Vaccine. 1994 Sep;12(12):1141-8 PMID: 7998425
  37. Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1.
    J Virol. 1995 Jun;69(6):3712-20 PMID: 7745720
  38. Isolation and characterization of a syncytium-inducing, macrophage/T-cell line-tropic human immunodeficiency virus type 1 isolate that readily infects chimpanzee cells in vitro and in vivo.
    J Virol. 1995 Jul;69(7):4453-62 PMID: 7769705
  39. Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages.
    Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):9004-8 PMID: 7568061
  40. Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.
    J Immunol. 1995 Oct 1;155(7):3638-44 PMID: 7561063
  41. Susceptibility of HIV-1 plasma virus to complement-mediated lysis. Evidence for a role in clearance of virus in vivo.
    J Immunol. 1996 Aug 15;157(4):1791-8 PMID: 8759769
  42. Safety and pharmacokinetics of hyperimmune anti-human immunodeficiency virus (HIV) immunoglobulin administered to HIV-infected pregnant women and their newborns. Pediatric AIDS Clinical Trials Group Protocol 185 Pharmacokinetic Study Group.
    J Infect Dis. 1997 Feb;175(2):283-91 PMID: 9203648
  43. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2001-07-00
Pages
6558-65
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC114379
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com